Gufic Biosciences Ltd

Stage 2 · Advancing · week 20Setup 8.3 ★★★ PrimeEven −0.1

As of 20 Nov 2026, Gufic Biosciences is in Stage 2, the uptrend phase, now in week 20 (since 1 Jul 2026). It closed at ₹418, 14.1% below its 52-week high and above its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. More about the company

₹418.3
Close, 20 Nov 2026
-3.16% on the day
₹4,194 Cr · Small cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dPharmaceuticals 42.4%-13.9 pts

Pro read

Pro

Our read

Uptrend, resting below its 50-day

Setup score

8.3 ★★★ Prime

RS rank

Edge

Even −0.1

GUFICBIO is about 5 months into its Stage 2 advance, 2% below its 50-day average and 14% under its 52-week high. A pause below the 50-day inside an uptrend is the weakest spot of the move until it closes back above the line.

Its relative strength is 84 of 99, a leader among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.

Stocks with a similar setup ran 0.1 points behind the average stock over the next 30 sessions on average, after costs, and their typical best close within 60 sessions was 17% above entry.

The trend read holds while it stays in Stage 2. A close below ₹426, its 50-day average, would put it at rest; ₹390, 20% under its 52-week high of ₹487, is where a trailing stop would sit.

Setup-score rank among Stage 2 peers: #19 of 50 in Pharmaceuticals · #24 of 61 in Health Care

Is GUFICBIO early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2023-08-24 → 2026-11-20
S2 38w
S4 33w
S2 20w
2023-08-242026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 11w → S3 4w → S2 13w → S3 10w → S2 38w → S3 5w → S4 10w → S1 12w → S4 3w → S1 4w → S4 33w → S1 5w → S2 20w current
Total tracked: 169 weeks across 13 stage runs.

GUFICBIO among Pharmaceuticals40th of 118 by relative strength

All 118 →
Stocks in Pharmaceuticals ranked by relative strength, with stage and one-month change
#StockStageRS1M
1BLISSGVSStage 2 · wk 4999+4.6%
2KPLStage 2 · wk 4499+20.5%
3FREDUNStage 2 · wk 3398+24.0%
4VENUSREMStage 3 · wk 1098−1.5%
5RUBICONStage 3 · wk 498+18.7%
6SAKARStage 2 · wk 5598+13.1%
7BAFNAPHStage 2 · wk 2398+1.9%
8INDSWFTLABStage 2 · wk 2398−7.4%
…40GUFICBIOStage 2 · wk 2084+7.4%
vs 52W High
-14.1%
₹273.5 lo₹487 hi
14.1% below 52W high, pullback range
How far this stock is from its 52-week high. A stock a little below its high with its Stage 2 structure intact is in a pullback, not a breakdown.
Stage Maturity
Week 20
1w13w26w
Week 20, proven structure
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
15.6%
200 DMA: ₹361.8 · rising
The stock is above its 200-day average, the long-term trend line. That is where a Stage 2 advance normally trades.
Rel Volume
0.38x
vs 50-day avg
Volume was well below average. In a Stage 2 advance, quiet sessions read as the stock resting, not being sold.
Trend Health
↑ ⇈
Short-term trend rising strongly, and accelerating
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+7.4%
3M
-0.8%
6M
+46.4%
YTD
+24.5%
1Y
+28.9%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
This stock ranks #33 of 58 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
42.4%
20d Δ
-13.9pp
1M return
+8.3%
3M return
+2.1%
Industry Stage-2 % · last 20 days
Ranks #28 of 48 Stage 2 stocks in this industry.

Mutual fund holdings

Held by 11 mutual funds in portfolios to October 2026: 7 active funds and 4 index funds and ETFs.

In October, among active funds: 1 increased and 1 reduced.

1 increased or opened1 reduced or exited
All 11 funds and what each did in October

Mutual funds holding GUFICBIO: the ten largest and the month’s moves →

Fund details on DiscoverMF

Scan Membership
In the scan on 19 Nov 2026
Last appeared 1 Sep 2026
Last appeared 1 Jul 2026
15 appearances in the last 60 days.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-11-20S2
Wk 20 · Vol 0.38x
2026-11-19S2
Wk 20 · Vol 0.39x
2026-11-18S2
Wk 20 · Vol 1.24x
2026-11-17S2
Wk 20 · Vol 0.71x
2026-11-16S2
Wk 19 · Vol 3.26x
2026-11-13S2
Wk 19 · Vol 1.72x
2026-11-12S2
Wk 19 · Vol 1.68x
2026-11-11S2
Wk 19 · Vol 3.44x
2026-11-09S2
Wk 19 · Vol 7.41x
2026-11-06S2
Wk 18 · Vol 0.46x
2026-11-05S2
Wk 18 · Vol 0.60x
2026-11-04S2
Wk 18 · Vol 1.24x
Moving averages & range
50 DMA
₹425.6
200 DMA
₹361.8
52W High
₹487
52W Low
₹273.5
5D Low
₹418.3
Resistance levels (recent highs)
20d High
₹487
60d High
₹487
120d High
₹487
250d High
₹487
Next resistance
+16.4%
to 20d High
P/E (TTM)
52.3
Forward —
Earnings Growth (YoY)
+39.3%
Revenue +21.6%
ROE
+11.9%
Profit margin +7.8%
Dividend Yield
0.02%
P/B 5.9

Gufic Biosciences: quick answers

What stage is Gufic Biosciences in?

As of 20 Nov 2026, Gufic Biosciences (GUFICBIO) is in Stage 2, the uptrend phase. It entered Stage 2 on 1 Jul 2026 and is in week 20. What the four stages mean

Is Gufic Biosciences in an uptrend?

Yes. Gufic Biosciences is in a Stage 2 uptrend. It trades 15.6% above its 200-day average, which is rising.

How far is Gufic Biosciences from its 52-week high?

Gufic Biosciences closed at ₹418 on 20 Nov 2026, 14.1% below its 52-week high of ₹487. Its 52-week low is ₹274.

How has Gufic Biosciences performed over the past year?

As of 20 Nov 2026, Gufic Biosciences is up 28.9% over the past year and up 24.5% so far in 2026.

Which sector and industry is Gufic Biosciences in?

Gufic Biosciences is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals

About this companyHealth Care· Pharmaceuticals

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. Further, it engages in contract and bulk drug manufacturing business. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.